How a virtual company leveraged data to accelerate drug development for neurodegenerative diseases
Find out how the virtual biotech company Libra Therapeutics leveraged data to accelerate drug development for neurodegenerative diseases.
External Contributor
About
Many authors are contributing to Labiotech.eu. If you want to join them, feel free to reach out to us with your article ideas.
Articles by External Contributor
Unlocking consistency in ATMP development: How cryopreservation strengthens Europe’s cell therapy supply chain
Discover how innovative cell therapy cryopreservation solutions are strengthening Europe’s ATMP supply chain.
The future of epilepsy treatment: pioneering advances and patient-centric care
Epilepsy, one of the most widespread neurological diseases in the world, characterized by recurrent seizures, affects approximately 50 million people globally. In Europe, up to six million people are estimated to be living with the disease. Whilst treatment options have come a long way over the last few decades, clinical practice still shows significant unmet […]
Sublingual delivery: the future for GLP-1 receptor agonists
Discover how GLP-1 receptor agonists, now thriving in obesity treatment, could benefit from a more patient-friendly sublingual delivery method.
Pink crisis, clear solution: how advanced mass spectrometry turned a manufacturing risk into success
Learn how KBI Biopharma used advanced mass spectrometry to address a cell culture media issue and prevent a potential manufacturing disruption.
Navigating your path to globalization: Untangling the regulatory maze of the Advanced Therapies supply chain
Discover how Cryoport Systems can help you navigate EMEA regulations and manage the supply chain complexities for advanced therapies.
ADVERTISEMENT
ADVERTISEMENT
Overcoming obstacles as advanced therapies continue to evolve in Europe
Discover strategies to overcome the challenges in advanced therapy development in Europe’s evolving biopharmaceutical landscape.
Cell avidity-tuning ensures safe CAR-T therapy for solid tumors
Learn more about the potential of cell avidity in designing potent and safe CAR-T treatments for solid tumors.
In Depth 21 Feb 2024
Cytokine release syndrome: how pharma is tackling a 21st century disease
Explore the frontier of biotech’s battle against cytokine release syndrome (CRS), from historical setbacks to cutting-edge solutions.
Opinion 18 Dec 2023
What to expect from biotech clinical trials in the coming year
As cancer research has seen an increase in funding lately, here are some of the key clinical trends that you can expect in 2024.
Opinion 29 Nov 2023
Redefining drug development: the trailblazing evolution of the pharmaceutical industry
Drug discovery and development is a long, costly, and high-risk process that takes over 10 to 15 years with an average cost of over $1 to $2 billion for each new drug to be approved for clinical use. For any pharmaceutical company or academic institution, it is a big achievement to advance a drug candidate […]
Opinion 1 Nov 2023
Could this be the start of a new era for PI3K drugs?
There is hope that a rich biotech pipeline will produce a second generation of PI3K drugs, a type of kinase inhibitor, after issues with the first generation from the class had brought up concerns. Phosphoinositide 3-kinases (PI3K) drugs work by inhibiting a pathway that plays a role in cell metabolism, growth, proliferation and survival that […]
ADVERTISEMENT
